Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Medacta Group stock

MOVE.SW
CH0468525222
A2PFTD

Price

122.98
Today +/-
-0.52
Today %
-0.42 %

Medacta Group stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Medacta Group stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Medacta Group stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Medacta Group stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Medacta Group's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Medacta Group Stock Price History

DateMedacta Group Price
2/3/2025122.98 undefined
1/31/2025123.50 undefined
1/30/2025123.81 undefined
1/29/2025122.75 undefined
1/28/2025118.11 undefined
1/27/2025116.49 undefined
1/24/2025116.76 undefined
1/23/2025116.99 undefined
1/22/2025117.42 undefined
1/21/2025117.36 undefined
1/20/2025116.44 undefined
1/17/2025118.51 undefined
1/16/2025118.95 undefined
1/15/2025120.33 undefined
1/14/2025115.88 undefined
1/13/2025115.46 undefined
1/10/2025118.88 undefined
1/9/2025120.89 undefined
1/8/2025120.85 undefined
1/7/2025121.62 undefined
1/6/2025122.34 undefined

Medacta Group Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Medacta Group, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Medacta Group from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Medacta Group’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Medacta Group. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Medacta Group’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Medacta Group’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Medacta Group’s growth potential.

Medacta Group Revenue, EBIT and net profit per share

DateMedacta Group RevenueMedacta Group EBITMedacta Group Net Income
2030e1.13 B undefined0 undefined0 undefined
2029e1.05 B undefined188.68 M undefined0 undefined
2028e975.66 M undefined170.65 M undefined0 undefined
2027e916.57 M undefined144.25 M undefined110.05 M undefined
2026e752.79 M undefined124.42 M undefined99.33 M undefined
2025e672.08 M undefined107.93 M undefined86.57 M undefined
2024e593.38 M undefined90.72 M undefined73.09 M undefined
2023510.78 M undefined75.72 M undefined47.36 M undefined
2022437.12 M undefined68.94 M undefined46.25 M undefined
2021363.13 M undefined66.59 M undefined51.52 M undefined
2020302.49 M undefined48.82 M undefined37.09 M undefined
2019310.62 M undefined57.81 M undefined11.86 M undefined
2018272.61 M undefined61.51 M undefined45.75 M undefined
2017244.68 M undefined49.66 M undefined33.5 M undefined
2016219.05 M undefined49.5 M undefined39.22 M undefined

Medacta Group Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)DIV. ()DIV. GROWTH (%)SHARES (M)DOCUMENTS
201620172018201920202021202220232024e2025e2026e2027e2028e2029e2030e
0.220.240.270.310.30.360.440.510.590.670.750.920.981.051.13
-11.4211.4813.97-2.5820.2020.3916.7016.2713.3211.9021.816.447.907.22
74.8974.5974.6372.9070.5371.9069.7968.0458.5251.6446.1437.8835.5932.9830.76
1641822032262132613053470000000
3933451137514647738699110000
--15.3836.36-75.56236.3637.84-9.802.1755.3217.8115.1211.11---
---------------
---------------
2020202020202019.990000000
---------------
Details

Keystats

ⓘ

Revenue and Growth

The Medacta Group Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Medacta Group is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (k)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (k)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20162017201820192020202120222023
               
21.2125.1233.9527.549.3720.433.0627.84
36.0836.8944.0948.0545.7859.4477.9694.65
2.022.894.167.425.427.867.216.85
67.3672.5189.23101.63114.19136.09160.3213.92
2.311.883.23.192.954.255.135.2
128.96139.29174.62187.79217.7228.03283.66348.47
100.87101.53132.91157.45153.36179.75218.5267.34
391364765456488479481712
8.1911.82000000
13.4931.8539.9445.5348.7451.9250.1351.36
059595959595959
17.7814.9117.3121.2821.5929.0331.6627.94
140.72160.52190.97224.78224.24261.23300.83347.4
269.68299.81365.6412.56441.94489.27584.49695.87
               
0.990.991.781.781.781.781.781.78
00021.2321.2321.2316.0210.49
142.97112.9393.03102.89139.41192.36239.88282.32
2.91-12.25-5.74-2.652.3111.0321.1443.53
00000000
146.87101.6789.07123.23164.72226.4278.81338.11
16.5217.2920.0517.8516.4825.9528.4838.85
20.7424.5542.0749.4447.8939.3445.7252.69
1.528.532.080.649.121.781.882.84
00000000
21.5441.7549.8652.5871.3269.4912.9855.03
60.3292.12114.06120.51144.81136.5689.06149.42
19.6455.87113.0299.5778.6963.17157.27146.95
33.9528.7631.2838.6536.2739.8444.6248.7
8.9121.3918.1730.617.4623.318.8920.77
62.5106.02162.47168.82132.41126.31220.77216.41
122.81198.14276.53289.33277.22262.87309.83365.83
269.68299.81365.6412.56441.93489.27588.65703.94
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Medacta Group provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Medacta Group's financial health and stability.

Assets

Medacta Group's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Medacta Group must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Medacta Group after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Medacta Group's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20162017201820192020202120222023
3933451137514647
1822243337405158
00000-400
-10-19-16-10-26-53-49-60
91511712152529
00021125
744382588
5651664259547375
-28-40-55-51-37-54-71-82
-33-44-49-42-34-52-65-80
-5-4593261
00000000
-66155-32-6-29164
000210-1-2-3
-9-1-9-10-6-313-10
-2.00-62.00-64.00----10.00-
0000000-11
1348-620-2711-11
28.0211.4711.28-8.9222.21-0.562.25-7.09
00000000

Medacta Group stock margins

The Medacta Group margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Medacta Group. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Medacta Group.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Medacta Group's sales revenue. A higher gross margin percentage indicates that the Medacta Group retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Medacta Group's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Medacta Group's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Medacta Group's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Medacta Group. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Medacta Group's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Medacta Group Margin History

Medacta Group Gross marginMedacta Group Profit marginMedacta Group EBIT marginMedacta Group Profit margin
2030e68.1 %0 %0 %
2029e68.1 %17.94 %0 %
2028e68.1 %17.49 %0 %
2027e68.1 %15.74 %12.01 %
2026e68.1 %16.53 %13.2 %
2025e68.1 %16.06 %12.88 %
2024e68.1 %15.29 %12.32 %
202368.1 %14.82 %9.27 %
202269.83 %15.77 %10.58 %
202171.94 %18.34 %14.19 %
202070.72 %16.14 %12.26 %
201973.05 %18.61 %3.82 %
201874.82 %22.56 %16.78 %
201774.63 %20.3 %13.69 %
201675.12 %22.6 %17.9 %

Medacta Group Stock Sales Revenue, EBIT, Earnings per Share

The Medacta Group earnings per share therefore indicates how much revenue Medacta Group has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Medacta Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Medacta Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Medacta Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Medacta Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Medacta Group Revenue, EBIT and net profit per share

DateMedacta Group Sales per ShareMedacta Group EBIT per shareMedacta Group Earnings per Share
2030e56.4 undefined0 undefined0 undefined
2029e52.6 undefined0 undefined0 undefined
2028e48.78 undefined0 undefined0 undefined
2027e45.83 undefined0 undefined5.5 undefined
2026e37.64 undefined0 undefined4.97 undefined
2025e33.6 undefined0 undefined4.33 undefined
2024e29.67 undefined0 undefined3.65 undefined
202325.55 undefined3.79 undefined2.37 undefined
202221.86 undefined3.45 undefined2.31 undefined
202118.15 undefined3.33 undefined2.58 undefined
202015.12 undefined2.44 undefined1.85 undefined
201915.53 undefined2.89 undefined0.59 undefined
201813.63 undefined3.08 undefined2.29 undefined
201712.23 undefined2.48 undefined1.67 undefined
201610.95 undefined2.47 undefined1.96 undefined

Medacta Group business model

The Medacta Group SA is a leading global company in the development, manufacturing, and marketing of medical devices and implants for the orthopedic industry. The company was founded in 1999 by Swiss entrepreneur Alberto Siccardi and is headquartered in Switzerland. The Medacta Group SA has its origins in one person - Alberto Siccardi. As a former athlete and successful entrepreneur, he had a vision that he put into action. He founded the Medacta Group and began focusing on the development and manufacturing of innovative orthopedic devices and implants. The Medacta Group has an innovative business model because the company is able to handle everything from research and development to marketing and sales of its products. This means that Medacta combines all steps from idea to end product under one roof and has complete control over the entire process. The Medacta Group SA is divided into three business areas: orthopedics, spine, and sports medicine. In the orthopedic field, the company manufactures hip and knee joint implants, as well as shoulder and elbow implants. Medacta also offers technologies that help extend the lifespan of artificial joints. In the spine field, the company provides instruments and implants for spine surgery. Medacta has a high level of expertise in this field and is known for innovative products that contribute to improving patient treatment. In the sports medicine field, the Medacta Group offers solutions for sports injuries. The company has developed a wide range of technologies and products that accelerate the healing process and support rehabilitation. Some of Medacta's most well-known products are the AMIS (Anterior Minimally Invasive Surgery) hip joint system and the GMK (General Medacta Knee) knee joint system. The AMIS system is a minimally invasive procedure for hip joint surgery that aims to shorten rehabilitation time and reduce the risk of complications. The GMK system is an innovative knee joint system that allows natural joint mechanics and approximates the natural knee pivot point. Medacta has also developed a range of software solutions that support surgeons in the planning and execution of operations. These solutions provide detailed visualizations and allow for precise planning of procedures. In conclusion, the Medacta Group SA is a global leader in the development and manufacturing of medical devices and implants for orthopedics, spine, and sports medicine. The company has an innovative business model that allows for complete control of the entire manufacturing process. Through the development of innovative products and technologies, the Medacta Group supports the treatment and rehabilitation of patients worldwide. Medacta Group is one of the most popular companies on Eulerpool.com.

Medacta Group SWOT Analysis

Strengths

Medacta Group SA has several strengths that contribute to its success in the market. Firstly, the company possesses a strong reputation for its innovative medical devices and solutions. This reputation has been built through years of research and development, leading to high-quality products. Additionally, Medacta Group SA has established strong relationships with healthcare professionals and institutions globally, which allows for widespread distribution and adoption of its products.

Weaknesses

Despite its strengths, Medacta Group SA also faces certain weaknesses that need to be addressed. One major weakness is the company's limited geographic presence compared to some of its competitors. Medacta Group SA primarily operates in Europe and Asia, which limits its market reach and potential for growth in other regions. Another weakness is the company's heavy reliance on a few key products for its revenue. This lack of diversification exposes Medacta Group SA to potential market volatility and competitive threats in the long term.

Opportunities

There are several opportunities that Medacta Group SA can capitalize on to further enhance its market position. Firstly, the growing global demand for minimally invasive surgical procedures presents a significant opportunity for Medacta Group SA's innovative medical devices. By continuing to invest in research and development, the company can develop new products that cater to this trend and gain a competitive edge. Additionally, expanding into untapped markets such as North America and Latin America can help Medacta Group SA diversify its revenue streams and reduce its dependence on specific regions.

Threats

Despite the opportunities, Medacta Group SA faces several threats that may hinder its growth and profitability. One major threat is intense competition in the medical device industry. Competitors with larger market shares and broader product portfolios pose a challenge to Medacta Group SA's market position. Additionally, stringent regulatory requirements and the need for rigorous clinical trials can increase the time and cost of bringing new products to market, potentially impacting Medacta Group SA's ability to stay ahead of the competition. Lastly, economic downturns and healthcare budget constraints in key markets can reduce the demand for medical devices, affecting Medacta Group SA's sales and profitability.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Medacta Group Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Medacta Group historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Medacta Group shares outstanding

The number of shares was Medacta Group in 2024 — This indicates how many shares 19.992 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Medacta Group earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Medacta Group's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Medacta Group’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Medacta Group's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Medacta Group dividend history and estimates

In 2024, Medacta Group paid a dividend amounting to 0.28 EUR. Dividend means that Medacta Group distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Medacta Group provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Medacta Group’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Medacta Group's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Medacta Group Dividend History

DateMedacta Group Dividend
2030e0.31 undefined
2029e0.31 undefined
2028e0.31 undefined
2027e0.31 undefined
2026e0.31 undefined
2025e0.31 undefined
2024e0.31 undefined
20230.27 undefined
20220.27 undefined

Medacta Group dividend payout ratio

In 2024, Medacta Group had a payout ratio of 11.57%. The payout ratio indicates the percentage of the company's profits that Medacta Group distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Medacta Group represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Medacta Group could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Medacta Group's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Medacta Group Payout Ratio History

DateMedacta Group Payout ratio
2030e11.57 %
2029e11.57 %
2028e11.57 %
2027e11.57 %
2026e11.57 %
2025e11.57 %
2024e11.57 %
202311.57 %
202211.57 %
202111.57 %
202011.57 %
201911.57 %
201811.57 %
201711.57 %
201611.57 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Medacta Group.

Eulerpool ESG Scorecard© for the Medacta Group stock

Eulerpool World ESG Rating (EESG©)

80/ 100

🌱 Environment

99

👫 Social

99

🏛️ Governance

42

Environment

Scope 1 - Direct Emissions
393
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
393
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees30
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Medacta Group shareholders

%
Name
Stocks
Change
Date
69.44964 % Family (Siccardi)13,889,928012/31/2023
3.22658 % Artisan Partners Limited Partnership645,316012/31/2023
1.08360 % GAM Investment Management (Switzerland) AG216,72007/31/2024
1.06749 % UBS Fund Management (Switzerland) AG213,498-8759/30/2024
0.90867 % The Vanguard Group, Inc.181,7345,6559/30/2024
0.87729 % SEB Asset Management (Denmark)175,458-4249/30/2024
0.75066 % Norges Bank Investment Management (NBIM)150,131-8,2236/30/2024
0.66281 % INVESCO Asset Management Limited132,56111,6768/31/2024
0.60096 % Florida State Board of Administration120,192-31,6746/30/2024
0.59747 % UBS Asset Management (Switzerland)119,4949689/30/2024
1
2
3
4
5
...
10

Medacta Group Executives and Management Board

Mr. Francesco Siccardi

(46)
Medacta Group Chief Executive Officer, Member of the Group Executive Management
Compensation 1.67 M

Mr. Alberto Siccardi

(79)
Medacta Group Non-Executive Chairman of the Board
Compensation 327,358

Mr. Victor Balli

(66)
Medacta Group Non-Executive Lead Independent Director
Compensation 217,268

Mr. Philippe Weber

(58)
Medacta Group Non-Executive Independent Director
Compensation 141,595

Mrs. Maria Siccardi Tonolli

(48)
Medacta Group Non-Executive Director
Compensation 127,911
1
2

Most common questions regarding Medacta Group

What values and corporate philosophy does Medacta Group represent?

Medacta Group SA represents values of innovation, excellence, and patient-centricity in the healthcare industry. As a leading medical device company, Medacta focuses on developing and providing cutting-edge surgical solutions to enhance patient outcomes and improve the quality of life. The company's corporate philosophy revolves around collaboration, integrity, and a strong commitment to continuous improvement. Medacta strives to establish long-term partnerships with surgical teams, ensuring the highest standards of safety and efficiency. By consistently prioritizing patient well-being and leveraging its technological expertise, Medacta Group SA remains at the forefront of advancing medical advancements and delivering top-notch surgical solutions globally.

In which countries and regions is Medacta Group primarily present?

Medacta Group SA is primarily present in Europe, the United States, and Asia. The company has a strong presence in countries such as Switzerland, Italy, Germany, France, Spain, the United Kingdom, and the Netherlands. Additionally, Medacta Group SA has established a significant footprint in North America, with a focus on the United States. The company's presence in Asia includes countries like Japan, China, South Korea, Malaysia, and Singapore. Medacta Group SA's global presence enables it to provide its innovative medical solutions and orthopedic products to a wide range of healthcare professionals and patients around the world.

What significant milestones has the company Medacta Group achieved?

Medacta Group SA has achieved several significant milestones. Firstly, the company has successfully expanded its global presence, operating in over 50 countries worldwide. Additionally, Medacta Group SA has demonstrated continuous innovation in the field of medical devices and orthopedic solutions. The company has received numerous accolades for its cutting-edge technologies and advanced research initiatives. Medacta Group SA has also shown resilience during challenging times, maintaining steady growth in revenue and market share. Overall, the company's commitment to excellence and dedication to improving patient outcomes have positioned Medacta Group SA as a trusted leader in the healthcare industry.

What is the history and background of the company Medacta Group?

Medacta Group SA is a leading Swiss medical device company specializing in orthopedic products and services. Founded in 1999 by Dr. Alberto Siccardi, Medacta has grown to become a trusted player in the global healthcare industry. The company focuses on developing innovative solutions for joint replacement, spine surgery, and sports medicine. With a strong commitment to research and development, Medacta has revolutionized surgical approaches and attained international recognition. Medacta's dedication to providing surgeons with state-of-the-art tools and patients with improved outcomes has led to its global success. As a reputable supplier in the medical field, Medacta Group SA continues to strive for excellence in its products and services for the benefit of patients worldwide.

Who are the main competitors of Medacta Group in the market?

The main competitors of Medacta Group SA in the market are other companies in the orthopedic medical device industry, such as Zimmer Biomet Holdings Inc., Stryker Corporation, and Johnson & Johnson. These companies also specialize in producing and marketing orthopedic implants and surgical instruments. Medacta Group SA faces competition from these established players, but it differentiates itself through its innovative product offerings, strong focus on customer satisfaction, and dedication to continuous research and development. Its commitment to providing high-quality orthopedic solutions positions Medacta Group SA as a leading player in the market.

In which industries is Medacta Group primarily active?

Medacta Group SA is primarily active in the medical industry. As an innovative medical device company, Medacta specializes in developing and manufacturing orthopedic implants and surgical instruments. With a focus on personalized solutions, the company offers products for various medical procedures, including joint replacement, spine surgery, and sports medicine. Leveraging advanced technologies and research expertise, Medacta aims to improve patient outcomes and enhance surgical techniques. With its unwavering commitment to innovation and quality, Medacta Group SA has established itself as a prominent player in the medical field.

What is the business model of Medacta Group?

Medacta Group SA operates under a medical technology business model. As a leading manufacturer in the orthopedic industry, Medacta specializes in designing, developing, and distributing innovative surgical solutions. The company is primarily focused on providing integrated solutions for joint replacement, spine surgery, and sports medicine. Medacta aims to improve patient outcomes by offering a comprehensive range of products, including implants, instruments, and computer-assisted technologies. With a commitment to research and development, Medacta continuously pushes the boundaries of medical technology, enabling healthcare professionals to deliver advanced and personalized care to patients worldwide.

What is the P/E ratio of Medacta Group 2025?

The Medacta Group P/E ratio is 28.4.

What is the P/S ratio of Medacta Group 2025?

The Medacta Group P/S ratio is 3.66.

What is the Quality Investing of Medacta Group?

The Quality Investing for Medacta Group is 4/10.

What is the revenue of Medacta Group 2025?

The expected Medacta Group revenue is 672.08 M EUR.

How high is the profit of Medacta Group 2025?

The expected Medacta Group profit is 86.57 M EUR.

What is the business model of Medacta Group

Medacta Group SA is a leading medical technology company specializing in the development, production, and marketing of innovative surgical solutions. The company operates globally and offers products and services in various business areas including orthopedics, spine, robotics, and traumatology. They also have expertise in digital health, offering solutions in telemedicine, risk management, and surgical planning. Their business model focuses on continuous improvement to provide high-quality products and collaborations with medical professionals to meet their needs. Through research and development, they aim to bring innovative technologies to the healthcare industry. Overall, Medacta Group SA offers a wide range of products and services tailored to the needs of healthcare professionals and patients, establishing themselves as a leading company in the medical technology industry.

What is the Medacta Group dividend?

Medacta Group pays a dividend of 0.27 EUR distributed over payouts per year.

How often does Medacta Group pay dividends?

The dividend cannot currently be calculated for Medacta Group or the company does not pay out a dividend.

What is the Medacta Group ISIN?

The ISIN of Medacta Group is CH0468525222.

What is the Medacta Group WKN?

The WKN of Medacta Group is A2PFTD.

What is the Medacta Group ticker?

The ticker of Medacta Group is MOVE.SW.

How much dividend does Medacta Group pay?

Over the past 12 months, Medacta Group paid a dividend of 0.27 EUR . This corresponds to a dividend yield of about 0.22 %. For the coming 12 months, Medacta Group is expected to pay a dividend of 0.31 EUR.

What is the dividend yield of Medacta Group?

The current dividend yield of Medacta Group is 0.22 %.

When does Medacta Group pay dividends?

Medacta Group pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Medacta Group?

Medacta Group paid dividends every year for the past 0 years.

What is the dividend of Medacta Group?

For the upcoming 12 months, dividends amounting to 0.31 EUR are expected. This corresponds to a dividend yield of 0.25 %.

In which sector is Medacta Group located?

Medacta Group is assigned to the 'Health' sector.

Wann musste ich die Aktien von Medacta Group kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Medacta Group from 5/14/2024 amounting to 0.275 EUR, you needed to have the stock in your portfolio before the ex-date on 5/10/2024.

When did Medacta Group pay the last dividend?

The last dividend was paid out on 5/14/2024.

What was the dividend of Medacta Group in the year 2024?

In the year 2024, Medacta Group distributed 0.27 EUR as dividends.

In which currency does Medacta Group pay out the dividend?

The dividends of Medacta Group are distributed in EUR.

All fundamentals about Medacta Group

Our stock analysis for Medacta Group Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medacta Group Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.